Exact Mass: 243.1582836
Exact Mass Matches: 243.1582836
Found 404 metabolites which its exact mass value is equals to given mass value 243.1582836,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Phencyclidine
D018377 - Neurotransmitter Agents > D018683 - Excitatory Amino Acid Agents > D018691 - Excitatory Amino Acid Antagonists D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D006213 - Hallucinogens C78272 - Agent Affecting Nervous System > C245 - Anesthetic Agent D004791 - Enzyme Inhibitors
3-Hydroxy-N-(2-oxotetrahydrofuran-3-yl)octanamide
Ipazine
C10H18ClN5 (243.12506580000002)
Agomelatine
C15H17NO2 (243.12592220000002)
Agomelatine is structurally closely related to melatonin. Agomelatine is a potent agonist at melatonin receptors and an antagonist at serotonin-2C (5-HT2C) receptors, tested in an animal model of depression. Agomelatine was discovered and developed by the European pharmaceutical company Servier Laboratories Ltd. Servier continue to develop the drug and conduct phase III trials in the European Union. In 2005 Servier submitted Agomelatine to the European Medicines Agency (EMEA). On 27 July 2006 the Committee for Medical Products for Human Use (CHMP) of the EMEA recommended a refusal of the marketing authorisation of Valdoxan/Thymanax. The major concern was that efficacy had not been sufficiently shown. In 2006 Servier sold the rights to develop Agomelatine in the US to Novartis. The development for the US market was discontinued in October 2011. It is currently sold in Australia under the Valdoxan trade name. D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants > D006993 - Hypnotics and Sedatives C78272 - Agent Affecting Nervous System > C66885 - Serotonin Antagonist C78272 - Agent Affecting Nervous System > C28197 - Antianxiety Agent N - Nervous system > N06 - Psychoanaleptics > N06A - Antidepressants Agomelatine (S-20098) is a specific agonist of MT1 and MT2 receptors with Kis of 0.1, 0.06, 0.12, and 0.27 nM for CHO-hMT1, HEK-hMT1, CHO-hMT2, and HEK-hMT2, respectively[1]. Agomelatine is a selective 5-HT2C receptor antagonist with pKis of 6.4 and 6.2 at native (porcine) and cloned, human 5-HT2C receptors, respectively[2].
N-Undecanoylglycine
N-Undecanoylglycine is an acylglycine with C-11 fatty acid group as the acyl moiety. Acylglycines 1 possess a common amidoacetic acid moiety and are normally minor metabolites of fatty acids. Elevated levels of certain acylglycines appear in the urine and blood of patients with various fatty acid oxidation disorders. They are normally produced through the action of glycine N-acyltransferase which is an enzyme that catalyzes the chemical reaction: acyl-CoA + glycine ↔ CoA + N-acylglycine. N-Undecanoylglycine is an acylglycine with C-11 fatty acid group as the acyl moiety.
Chalciporone
7-Methyl-2-(7-oxo-1,3-nonadienyl)-3H-azepine is found in mushrooms. 7-Methyl-2-(7-oxo-1,3-nonadienyl)-3H-azepine is a constituent of the toxic mushroom Chalciporus piperatus. Pungent principle from fruit-bodies of the toxic mushroom Chalciporus piperatus. Chalciporone is found in mushrooms.
Prolyl-Lysine
Prolyl-Lysine is a dipeptide composed of proline and lysine. It is an incomplete breakdown product of protein digestion or protein catabolism. Some dipeptides are known to have physiological or cell-signaling effects although most are simply short-lived intermediates on their way to specific amino acid degradation pathways following further proteolysis. This dipeptide has not yet been identified in human tissues or biofluids and so it is classified as an Expected metabolite.
Prolyl-Glutamine
Prolyl-Glutamine is a dipeptide composed of proline and glutamine. It is an incomplete breakdown product of protein digestion or protein catabolism. Some dipeptides are known to have physiological or cell-signaling effects although most are simply short-lived intermediates on their way to specific amino acid degradation pathways following further proteolysis. This dipeptide has not yet been identified in human tissues or biofluids and so it is classified as an Expected metabolite.
Tiglylcarnitine
Tiglylcarnitine is an acylcarnitine. More specifically, it is an tiglic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Tiglylcarnitine is therefore classified as a short chain AC. As a short-chain acylcarnitine Tiglylcarnitine is a member of the most abundant group of carnitines in the body, comprising more than 50\\% of all acylcarnitines quantified in tissues and biofluids (PMID: 31920980). Some short-chain carnitines have been studied as supplements or treatments for a number of diseases, including neurological disorders and inborn errors of metabolism. In particular Tiglylcarnitine is elevated in the blood or plasma of individuals with beta ketothiolase deficiency/acat1 gene mutation (PMID: 27264805, PMID: 14518824, PMID: 3435793), and ECHS1 deficiency (PMID: 31908952). It is also decreased in the blood or plasma of individuals with familial mediterranean fever (PMID: 29900937), carcinoma, lewis lung (PMID: 30839735), metabolic syndrome, type 2 diabetes mellitus, and cardiovascular diseases (PMID: 24710945). Tiglylcarnitine is also detected in the urinary organic acid and blood spot acylcarnitine profiles in patients with mitochondrial acetoacetyl-CoA thiolase (T2) deficiency, an inborn error of metabolism affecting isoleucine and ketone bodies in the catabolic process (PMID: 14518824 ). Tiglylcarnitine is found to be associated with celiac disease, which is also an inborn error of metabolism. Tiglylcarnitine has been identified in the human placenta (PMID: 32033212 ). Carnitine acetyltransferase (CrAT, EC:2.3.1.7) is responsible for the synthesis of all short-chain and short branched-chain acylcarnitines (PMID: 23485643). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews]. Tiglylcarnitine is detected in the urinary organic acid and blood spot acylcarnitine profiles in patients with
Frovatriptan
Frovatriptan, also known as Frova (trade name), belongs to a class of medications known as 5-hydroxytryptamine agonists (triptan) (PMID: 18001261). It is widely indicated for the treatment of migraine headaches with or without aura in adults (PMID: 22900951, 27103792). It works in the brain to relieve migraine symptoms including headache, pain, nausea, vomiting, sensitivity to light/sound. However, it is not used to treat patients with hemiplegic, ophthalmoplegic or basilar migraine. Frovatriptan binds with high affinity for serotonin 5-HT1B and 5-HT1D receptors, thereby relieving pain by narrowing blood vessels (PMID: 11735616, 12517245). Patient’s may experience some side effects, especially who have heart or blood vessel disease. Frovatriptan is only found in individuals who have consumed or used this drug. N - Nervous system > N02 - Analgesics > N02C - Antimigraine preparations > N02CC - Selective serotonin (5ht1) agonists D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D017366 - Serotonin Receptor Agonists C78272 - Agent Affecting Nervous System > C47794 - Serotonin Agonist
Glutaminylproline
Glutaminylproline is a dipeptide composed of glutamine and proline. It is an incomplete breakdown product of protein digestion or protein catabolism. Some dipeptides are known to have physiological or cell-signaling effects although most are simply short-lived intermediates on their way to specific amino acid degradation pathways following further proteolysis.
Lysylproline
Lysylproline is a dipeptide composed of lysine and proline. It is an incomplete breakdown product of protein digestion or protein catabolism. Dipeptides are organic compounds containing a sequence of exactly two alpha-amino acids joined by a peptide bond. Some dipeptides are known to have physiological or cell-signalling effects although most are simply short-lived intermediates on their way to specific amino acid degradation pathways following further proteolysis.
Prolyl-Gamma-glutamate
Prolyl-Gamma-glutamate is a dipeptide composed of proline and gamma-glutamate. It is an incomplete breakdown product of protein digestion or protein catabolism. Some dipeptides are known to have physiological or cell-signaling effects although most are simply short-lived intermediates on their way to specific amino acid degradation pathways following further proteolysis. This dipeptide has not yet been identified in human tissues or biofluids and so it is classified as an Expected metabolite.
2-Ethylacryloylcarnitine
2-Ethylacryloylcarnitine is an acylcarnitine. More specifically, it is an ethacrylic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 2-Ethylacryloylcarnitine is therefore classified as a short chain AC. As a short-chain acylcarnitine 2-Ethylacryloylcarnitine is a member of the most abundant group of carnitines in the body, comprising more than 50\\% of all acylcarnitines quantified in tissues and biofluids (PMID: 31920980). Some short-chain carnitines have been studied as supplements or treatments for a number of diseases, including neurological disorders and inborn errors of metabolism. Carnitine acetyltransferase (CrAT, EC:2.3.1.7) is responsible for the synthesis of all short-chain and short branched-chain acylcarnitines (PMID: 23485643). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
4-Tiglylcarnitine
4-Tiglylcarnitine is an acylcarnitine. More specifically, it is an pent-4-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 4-Tiglylcarnitine is therefore classified as a short chain AC. As a short-chain acylcarnitine 4-Tiglylcarnitine is a member of the most abundant group of carnitines in the body, comprising more than 50\\% of all acylcarnitines quantified in tissues and biofluids (PMID: 31920980). Some short-chain carnitines have been studied as supplements or treatments for a number of diseases, including neurological disorders and inborn errors of metabolism. In particular 4-Tiglylcarnitine is elevated in the blood or plasma of individuals with beta ketothiolase deficiency/acat1 gene mutation (PMID: 27264805, PMID: 14518824, PMID: 3435793), and ECHS1 deficiency (PMID: 31908952). It is also decreased in the blood or plasma of individuals with familial mediterranean fever (PMID: 29900937), carcinoma, lewis lung (PMID: 30839735), metabolic syndrome, type 2 diabetes mellitus, and cardiovascular diseases (PMID: 24710945). Carnitine acetyltransferase (CrAT, EC:2.3.1.7) is responsible for the synthesis of all short-chain and short branched-chain acylcarnitines (PMID: 23485643). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
(3E)-Tiglylcarnitine
(3E)-Tiglylcarnitine is an acylcarnitine. More specifically, it is an (3E)-pent-3-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (3E)-Tiglylcarnitine is therefore classified as a short chain AC. As a short-chain acylcarnitine (3E)-Tiglylcarnitine is a member of the most abundant group of carnitines in the body, comprising more than 50\\% of all acylcarnitines quantified in tissues and biofluids (PMID: 31920980). Some short-chain carnitines have been studied as supplements or treatments for a number of diseases, including neurological disorders and inborn errors of metabolism. In particular (3E)-Tiglylcarnitine is elevated in the blood or plasma of individuals with beta ketothiolase deficiency/acat1 gene mutation (PMID: 27264805, PMID: 14518824, PMID: 3435793), and ECHS1 deficiency (PMID: 31908952). It is also decreased in the blood or plasma of individuals with familial mediterranean fever (PMID: 29900937), carcinoma, lewis lung (PMID: 30839735), metabolic syndrome, type 2 diabetes mellitus, and cardiovascular diseases (PMID: 24710945). Carnitine acetyltransferase (CrAT, EC:2.3.1.7) is responsible for the synthesis of all short-chain and short branched-chain acylcarnitines (PMID: 23485643). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
2-Tiglylcarnitine
2-Tiglylcarnitine is an acylcarnitine. More specifically, it is an pent-2-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 2-Tiglylcarnitine is therefore classified as a short chain AC. As a short-chain acylcarnitine 2-Tiglylcarnitine is a member of the most abundant group of carnitines in the body, comprising more than 50\\% of all acylcarnitines quantified in tissues and biofluids (PMID: 31920980). Some short-chain carnitines have been studied as supplements or treatments for a number of diseases, including neurological disorders and inborn errors of metabolism. In particular 2-Tiglylcarnitine is elevated in the blood or plasma of individuals with beta ketothiolase deficiency/acat1 gene mutation (PMID: 27264805, PMID: 14518824, PMID: 3435793), and ECHS1 deficiency (PMID: 31908952). It is also decreased in the blood or plasma of individuals with familial mediterranean fever (PMID: 29900937), carcinoma, lewis lung (PMID: 30839735), metabolic syndrome, type 2 diabetes mellitus, and cardiovascular diseases (PMID: 24710945). Carnitine acetyltransferase (CrAT, EC:2.3.1.7) is responsible for the synthesis of all short-chain and short branched-chain acylcarnitines (PMID: 23485643). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
3-Methylbut-2-enoylcarnitine
3-methylbut-2-enoylcarnitine is an acylcarnitine. More specifically, it is an 3-methylbut-2-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3-methylbut-2-enoylcarnitine is therefore classified as a short chain AC. As a short-chain acylcarnitine 3-methylbut-2-enoylcarnitine is a member of the most abundant group of carnitines in the body, comprising more than 50\\% of all acylcarnitines quantified in tissues and biofluids (PMID: 31920980). Some short-chain carnitines have been studied as supplements or treatments for a number of diseases, including neurological disorders and inborn errors of metabolism. Carnitine acetyltransferase (CrAT, EC:2.3.1.7) is responsible for the synthesis of all short-chain and short branched-chain acylcarnitines (PMID: 23485643). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
N-((1R,2S,4S)-Bicyclo[2.2.1]heptan-2-yl)-9-methyl-9H-purin-6-amine
Atanine
C15H17NO2 (243.12592220000002)
Atanine is a natural product found in Ravenia spectabilis, Zanthoxylum zanthoxyloides, and Zanthoxylum wutaiense with data available.
2-Heptyl-4-hydroxyquinoline
A monohydroxyquinoline that is 4-hydroxyquinoline bearing an additional heptyl substituent at position 2.
1-Azabicyclo[2.2.2]octan-3-one, 2-[(4-methoxyphenyl)methylene]-
C15H17NO2 (243.12592220000002)
2(1H)-quinolinone, 4-hydroxy-1-methyl-3-(3-methyl-2-butenyl)-
C15H17NO2 (243.12592220000002)
(2E,4E)-N-isobutyldodeca-2,4-dien-8,10-diynamide|2-Methylpropylamide-(2E,4E)-2,4-Dodecadiene-8,10-diynoic acid|Anacydin|dodeca-2E,4E-diene-8,10-diynoic acid isobutylamide|Dodecadien-(2trans.4trans)-diin-(8.10)-saeure-(1)-isobutylamid
4-(2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)butan-1-amine
5-Methoxy-2,2-dimethyl-4H-pyrano[2,3-b]chinolin
C15H17NO2 (243.12592220000002)
(E)-3-(5-acetoxy-3-methylpent-2-enamido)propanoic acid|pestalotiopamide E
C11H17NO5 (243.11066720000002)
2-allyl-5-(pent-2-en-4-ynyl)-cis-decahydroquinoline
N-(2-methylbutyl)undeca-2E,4Z-diene-8,10-diynamide|undeca-2E,4Z-dien-8,10-diynoic acid 2-methylbutylamide|undeca-2E,4Z-diene-8,10-diynoic acid 2-methylbutylamide|undeca-2E,4Z-diene-8,10-diynoic acid-2-methylbutylamide
2,2,10-trimethyl-2,3,4,10-tetrahydro-5H-pyrano[2,3-b]quinolin-5-one
C15H17NO2 (243.12592220000002)
2-{[1-(2-Amino-acetyl)-pyrrolidine-2-carbonyl]-amino}-propionic acid
Agomelatine
C15H17NO2 (243.12592220000002)
D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants > D006993 - Hypnotics and Sedatives C78272 - Agent Affecting Nervous System > C66885 - Serotonin Antagonist C78272 - Agent Affecting Nervous System > C28197 - Antianxiety Agent N - Nervous system > N06 - Psychoanaleptics > N06A - Antidepressants Agomelatine (S-20098) is a specific agonist of MT1 and MT2 receptors with Kis of 0.1, 0.06, 0.12, and 0.27 nM for CHO-hMT1, HEK-hMT1, CHO-hMT2, and HEK-hMT2, respectively[1]. Agomelatine is a selective 5-HT2C receptor antagonist with pKis of 6.4 and 6.2 at native (porcine) and cloned, human 5-HT2C receptors, respectively[2].
PHENCYCLIDINE
D018377 - Neurotransmitter Agents > D018683 - Excitatory Amino Acid Agents > D018691 - Excitatory Amino Acid Antagonists D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D006213 - Hallucinogens C78272 - Agent Affecting Nervous System > C245 - Anesthetic Agent D004791 - Enzyme Inhibitors
3-hydroxy-C8-homoserine lactone
CONFIDENCE standard compound; INTERNAL_ID 215
(2R,5S)-2-allyl-5-((E)-pent-2-en-4-yn-1-yl)decahydroquinoline
(2R,5R)-2-allyl-5-((E)-pent-2-en-4-yn-1-yl)decahydroquinoline
(2R,5S,8aS)-2-allyl-5-((E)-pent-2-en-4-yn-1-yl)decahydroquinoline
(5S,8R)-8-(but-3-en-1-yl)-5-((E)-pent-2-en-4-yn-1-yl)octahydroindolizine
(5S,8R)-8-ethyl-5-((1E,4E)-hepta-1,4-dien-6-yn-1-yl)octahydroindolizine
8-ethyl-5-(hept-4-en-6-yn-1-yl)-1,2,3,5,8,8a-hexahydroindolizine
1-((4-amino-2-propylpyrimidin-5-yl)methyl)-2-methylpyridinium
Frovatriptan
N - Nervous system > N02 - Analgesics > N02C - Antimigraine preparations > N02CC - Selective serotonin (5ht1) agonists D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D017366 - Serotonin Receptor Agonists C78272 - Agent Affecting Nervous System > C47794 - Serotonin Agonist
Lys-pro
A dipeptide formed from L-lysine and L-proline residues.
Pro-GLN
A dipeptide formed from L-proline and L-glutamine residues.
Pro-lys
A dipeptide formed from L-proline and L-lysine residues.
1-O-tert-butyl 3-O-methyl (3R)-piperidine-1,3-dicarboxylate
(1-Furan-2-yl-but-3-enyl)-(4-methoxy-phenyl)-amine
C15H17NO2 (243.12592220000002)
1-(tert-butoxycarbonyl)-3-methylpiperidine-3-carboxylic acid
TERT-BUTYL 2-(TRIMETHYLSILYL)PYRROLIDINE-1-CARBOXYLATE
C12H25NO2Si (243.16544700000003)
1-tert-Butyl 2-methyl 2-methylpyrrolidine-1,2-dicarboxylate
tert-butyl 4-amino-4-carbamoylpiperidine-1-carboxylate
4-OXO-PIPERIDINE-1,3-DICARBOXYLIC ACID 1-TERT-BUTYL ESTER
C11H17NO5 (243.11066720000002)
(4S,6R)-6-BENZYLOXYMETHYL-4-METHYL-4-VINYL-TETRAHYDRO-PYRAN-2-ONE
1-(1H-INDOLE-3-YL)-2-PYRROLIDIN-1-YL-ETHYL]-METHYL-AMINE
tert-Butyl 4-acetyl-2,2-dimethyloxazolidine-3-carboxylate
4-(3-methylbutoxy)pyridine-2-carboximidamide,hydrochloride
C11H18ClN3O (243.11383279999998)
4-(Pentyloxy)picolinimidamide hydrochloride
C11H18ClN3O (243.11383279999998)
2-[(2S)-1-[(2-methylpropan-2-yl)oxycarbonyl]-5-oxopyrrolidin-2-yl]acetic acid
C11H17NO5 (243.11066720000002)
2-Naphthalenol,1-(4-morpholinylmethyl)-
C15H17NO2 (243.12592220000002)
3-(3-PHENOXYPHENYL)-DL-BETA-ALANINOL
C15H17NO2 (243.12592220000002)
TERT-BUTYL 3-(HYDRAZINECARBONYL)PIPERIDINE-1-CARBOXYLATE
3-[2[[(1,1-DIMETHYLETHYL)DIMETHYL SILYL]OXY]ETHYL]-PIPERIDINE
1,2,3,5-Tetrahydro-spiro[4H-1-benzazepine-4,1-[2]cyclopentene]-3-carboxylic acid
C15H17NO2 (243.12592220000002)
2-aminopropan-1-ol,propane-1,2-diol,propane-1,2,3-triol
4-((4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)methyl)benzonitrile
C14H18BNO2 (243.14305180000002)
2-((4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)METHYL)BENZONITRILE
C14H18BNO2 (243.14305180000002)
3-(1,2,3,4-tetrahydrocarbazol-9-yl)propanoic acid
C15H17NO2 (243.12592220000002)
Indole-7-boronic acid pinacol ester
C14H18BNO2 (243.14305180000002)
Indole-6-boronic acid pinacol ester
C14H18BNO2 (243.14305180000002)
Cyclopentaneacetic acid, 1-[[(1,1-dimethylethoxy)carbonyl]amino]- (9CI)
N-Boc-4-oxo-L-proline methyl ester
C11H17NO5 (243.11066720000002)
Indole-4-boronic acid pinacol ester
C14H18BNO2 (243.14305180000002)
1-(4-DIMETHYLAMINO-2-FLUORO-PHENYL)-3-(4-DIMETHYLIMMONIUM-2-FLUORO-CYCLOHEXA-2,5-DIEN-1-YLIDENE)-2-OXO-CYCLOBUTEN-4-OLATE
C15H17NO2 (243.12592220000002)
4-[(2-Fluorophenyl)azo]-N,N-dimethylbenzenamine
C14H14FN3 (243.11716959999998)
5-Indoleboronic acid pinacol ester
C14H18BNO2 (243.14305180000002)
3-methyl-1-[(2-methylpropan-2-yl)oxycarbonyl]piperidine-2-carboxylic acid
ethyl 2,5-dimethyl-1-phenylpyrrole-3-carboxylate
C15H17NO2 (243.12592220000002)
(1S,3R)-3-((TERT-BUTOXYCARBONYL)AMINO)CYCLOHEXANECARBOXYLIC ACID
4-Cyano-4-phenylcyclohexanone ethylene ketal
C15H17NO2 (243.12592220000002)
2-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzonitrile
C14H18BNO2 (243.14305180000002)
1-Tert-Butoxycarbonylamino-Cyclohexanecarboxylic Acid
2-METHYL-5-CYANOPHENYL BORONIC ACID PINACOL ESTER
C14H18BNO2 (243.14305180000002)
tetraethylammonium trifluoroacetate
C10H20F3NO2 (243.14460560000003)
4-(Cyanomethyl)benzeneboronic acid pinacol ester
C14H18BNO2 (243.14305180000002)
(R)-TERT-BUTYL 2,2-DIMETHYL-4-(2-OXOETHYL)OXAZOLIDINE-3-CARBOXYLATE
(3S,4R,5R,6S)-4-OXO-PENTANOICACID4,5-BIS-BENZYLOXY-6-BENZYLOXYMETHYL-2-P-TOLYLSULFAN
1-(TERT-BUTOXYCARBONYL)-3-OXOPIPERIDINE-4-CARBOXYLIC ACID
C11H17NO5 (243.11066720000002)
6-ETHYL-2-METHYLQUINOLINE-3-CARBOXYLIC ACID ETHYL ESTER
C15H17NO2 (243.12592220000002)
(3-PIPERAZIN-1-YL-PROPYL)-CARBAMIC ACID TERT-BUTYL ESTER
(S)-1-(tert-Butoxycarbonyl)-4,4-dimethylpyrrolidine-2-carboxylic acid
1-[2-(1H-Indol-3-yl)-ethyl]-5-oxo-pyrrolidine-3-carboxylicacid
tert-butyl 3-(2-methoxy-2-oxoethyl)pyrrolidine-1-carboxylate
2-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzonitrile
C14H18BNO2 (243.14305180000002)
(3R,4R)-1-[(tert-butoxy)carbonyl]-4-ethylpyrrolidine-3-carboxyli
4-OXO-PIPERIDINE-1-CARBOXYLIC ACID 2-TRIMETHYLSILANYL-ETHYL ESTER
tert-butyl 4-(2-methoxyethyl)piperidine-1-carboxylate
(R)-2-(1-(tert-Butoxycarbonyl)piperidin-3-yl)acetic acid
TERT-BUTYL 3-(N-HYDROXYCARBAMIMIDOYL)PIPERIDINE-1-CARBOXYLATE
(S)-ETHYL 1-(2-METHOXY-2-OXOACETYL)PIPERIDINE-2-CARBOXYLATE
C11H17NO5 (243.11066720000002)
1-(TERT-BUTOXYCARBONYL)-4-METHYLPIPERIDINE-3-CARBOXYLIC ACID
2-{[(tert-butoxy)carbonyl]amino}-3-cyclobutylpropanoic acid
2-AMINO-1-(4-BENZYLOXYPHENYL)ETHANOL
C15H17NO2 (243.12592220000002)
5-(BENZYLAMINOMETHYL)-2-METHOXYPHENOL
C15H17NO2 (243.12592220000002)
1,1-Bis(4-methoxyphenyl)methanamine
C15H17NO2 (243.12592220000002)
N-(1-Methylethyl)-3-(1-Naphthalenyloxy)-1-Propanamine
2-(3-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)PHENYL)ACETONITRILE
C14H18BNO2 (243.14305180000002)
tert-butyl N-[2-oxo-2-(piperazin-1-yl)ethyl]carbamate
3-(1-(TERT-BUTOXYCARBONYL)PYRROLIDIN-3-YL)PROPANOIC ACID
4-(BENZYLAMINOMETHYL)-2-METHOXYPHENOL
C15H17NO2 (243.12592220000002)
4-PHENYL-1-PIPERIDIN-4-YL-1,3-DIHYDRO-2H-IMIDAZOL-2-ONE
1H-INDOLE-2-BORONIC ACID PINACOL ESTER
C14H18BNO2 (243.14305180000002)
tert-butyl 2-(2-methoxy-2-oxoethyl)pyrrolidine-1-carboxylate
1H-Indole,2-(1,1-dimethylethyl)-2,3-dihydro-5-(trifluoromethyl)-(9CI)
(2R,4S,5R)-TERT-BUTYL 5-(2-HYDROXYETHYL)-2-METHYLPIPERIDINE-4-CARBOXYLATE
tert-butyl 4-(2-oxoethoxy)piperidine-1-carboxylate
(1S,3S)-N-BOC-1-AMINOCYCLOPENTANE-3-CARBOXYLIC ACID METHYL ESTER
(2S)-2-HYDROXY-3-METHYL-N-[(2S)-1-{[(1S)-3-METHYL-2-OXO-2,3,4,5-TETRAHYDRO-1H-3-BENZAZEPIN-1-YL]AMINO}-1-OXOPROPAN-2-YL]BUTANAMIDE
3-cyclobutyl-3-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid
cis-3-{[(tert-butoxy)carbonyl]amino}cyclohexane-1-carboxylic acid
ethyl 2,5,7-trimethylquinoline-3-carboxylate
C15H17NO2 (243.12592220000002)
2,5,8-TRIMETHYLQUINOLINE-3-CARBOXYLIC ACID ETHYL ESTER
C15H17NO2 (243.12592220000002)
ethyl 2,6,8-trimethylquinoline-3-carboxylate
C15H17NO2 (243.12592220000002)
3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indole
C14H18BNO2 (243.14305180000002)
tert-butyl 3-(3-hydroxypropyl)piperidine-1-carboxylate
tert-butyl 2-(3-hydroxypropyl)piperidine-1-carboxylate
4,4-dimethoxy-n-methyldiphenylamine
C15H17NO2 (243.12592220000002)
tert-Butyl 4-(2-hydroxyethyl)-4-methylpiperidine-1-carboxylate
tert-butyl 3-(2-ethoxy-2-oxoethyl)azetidine-1-carboxylate
tert-butyl 4-(methylcarbamoyl)piperazine-1-carboxylate
Quinoline, 6-(triethylsilyl)- (9CI)
C15H21NSi (243.14431860000002)
Ethyl 1-[ethoxy(oxo)acetyl]-L-prolinate
C11H17NO5 (243.11066720000002)
tert-Butyl 4-(3-hydroxypropyl)tetrahydro-1(2H)-pyridinecarboxylate
(S)-tert-Butyl 2,2-dimethyl-4-(2-oxoethyl)oxazolidine-3-carboxylate
N-(1-(2-HYDROXY-NAPHTHALEN-1-YL)-PROPYL)-ACETAMIDE
C15H17NO2 (243.12592220000002)
(3,4-DIMETHOXY-BENZYL)-PHENYL-AMINE
C15H17NO2 (243.12592220000002)
6-((2R,6S)-2,6-dimethylmorpholino)pyridin-3-amine hydrochloride
C11H18ClN3O (243.11383279999998)
3-Cyclohexyl-1H-indole-6-carboxylic acid
C15H17NO2 (243.12592220000002)
N-METHYL-1-(1,3,5-TRIMETHYL-1H-PYRAZOL-4-YL)METHANAMINE
TRANS-2-((TERT-BUTOXYCARBONYL)AMINO)CYCLOHEXANECARBOXYLIC ACID
(S)-2-(tert-butoxycarbonylamino)-3-cyclobutylpropanoic acid
(R)-2-(tert-butoxycarbonylamino)-3-cyclobutylpropanoic acid
1-(2,5-Dimethoxy-4-i-propylthiophenyl)-2-aminopropane
2-(5,5-Dimethyl-1,3,2-dioxaborinan-2-yl)-1-methyl-1H-indole
C14H18BNO2 (243.14305180000002)
Boc-L-Pyroglutamic acid methyl ester
C11H17NO5 (243.11066720000002)
(S)-tert-Butyl (1-cyclohexyl-2-hydroxyethyl)carbamate
tert-Butyl 4-(3-aminopropyl)piperazine-1-carboxylate
(R)-1-tert-Butyl 2-methyl 5-oxopyrrolidine-1,2-dicarboxylate
C11H17NO5 (243.11066720000002)
3-Methyl-5-(4,4,5,5-tetramethyl[1,3,2]dioxaborolan-2-yl)benzonitrile
C14H18BNO2 (243.14305180000002)
1-Benzyl-4-(dimethylamino)piperidine-4-carbonitrile
(S)-TERT-BUTYL 4-(2-AMINOPROPYL)PIPERAZINE-1-CARBOXYLATE
Tepilamide fumarate
C11H17NO5 (243.11066720000002)
C308 - Immunotherapeutic Agent
Somantadine hydrochloride
C254 - Anti-Infective Agent > C281 - Antiviral Agent
1,3,5-Triazine-2,4-diamine, N-ethyl-N-(1-methylethyl)-6-(methylsulfinyl)-
Ethanamine, N,N-diethyl-2-(4-methylphenoxy)-, hydrochloride
C13H22ClNO (243.13898319999998)
Amprolium ion
C14H19N4+ (243.16096339999999)
D000890 - Anti-Infective Agents > D000977 - Antiparasitic Agents > D000981 - Antiprotozoal Agents
(2E)-2-[(4-methoxyphenyl)methylidene]-1-azabicyclo[2.2.2]octan-3-one
C15H17NO2 (243.12592220000002)
3-Methylbut-2-enoylcarnitine
3-methylbut-2-enoylcarnitine is an acylcarnitine. More specifically, it is an 3-methylbut-2-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3-methylbut-2-enoylcarnitine is therefore classified as a short chain AC. As a short-chain acylcarnitine 3-methylbut-2-enoylcarnitine is a member of the most abundant group of carnitines in the body, comprising more than 50\\% of all acylcarnitines quantified in tissues and biofluids (PMID: 31920980). Some short-chain carnitines have been studied as supplements or treatments for a number of diseases, including neurological disorders and inborn errors of metabolism. Carnitine acetyltransferase (CrAT, EC:2.3.1.7) is responsible for the synthesis of all short-chain and short branched-chain acylcarnitines (PMID: 23485643). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
3-Hydroxymorphinan
D002492 - Central Nervous System Depressants > D009294 - Narcotics > D053610 - Opiate Alkaloids
3-Hydroxytetradecanoate
A 3-hydroxy fatty acid anion that is the conjugate base of 3-hydroxytetradecanoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.
2-Hydroxymyristate
A 2-hydroxy fatty acid anion that is the conjugate base of 2-hydroxymyristic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.
2-[(8,9-dihydro-7H-purin-6-ylamino)methyl]phenol
C12H13N5O (243.11200480000002)
4-[(8,9-dihydro-7H-purin-6-ylamino)methyl]phenol
C12H13N5O (243.11200480000002)
3-[(8,9-dihydro-7H-purin-6-ylamino)methyl]phenol
C12H13N5O (243.11200480000002)
(2S)-2-amino-5-oxo-5-[[(3S)-2-oxopiperidin-3-yl]amino]pentanoic acid
(2S)-2-hydroxytetradecanoate
A (2S)-2-hydroxy fatty acid anion that is the conjugate base of (2S)-2-hydroxytetradecanoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.
14-Hydroxymyristate
A long-chain fatty acid anion that is the conjugate base of 14-hydroxymyristic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.
2-methyl-N-(2,4,6-trimethylphenyl)-3-furancarboxamide
C15H17NO2 (243.12592220000002)
N-(2,3-dimethylphenyl)bicyclo[2.2.1]heptane-2-carboxamide
(2R)-2-hydroxytetradecanoate
A (2R)-2-hydroxy fatty acid anion that is the conjugate base of (2R)-2-hydroxytetradecanoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.
2-Cyano-N,N-diethyl-2-(phenyl-hydrazono)-acetamidine
(2S)-2-[[2-[[(2S)-pyrrolidine-2-carbonyl]amino]acetyl]amino]propanoic Acid
13-Hydroxytetradecanoate
An (omega-1)-hydroxy fatty acid anion that is the conjugate base of 13-hydroxymyristic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.
N-(2,4-dimethylphenyl)-3-bicyclo[2.2.1]heptanecarboxamide
huperzine A(1+)
C15H19N2O+ (243.14973039999998)
A primary ammonium ion that is the conjugate acid of huperzine A resulting from the protonation of the primary amino group; major species at pH 7.3.
(7S)-7-[propyl(prop-2-ynyl)amino]-5,6,7,8-tetrahydronaphthalen-1-ol
(S)-1-((S)-2,6-Diaminohexanoyl)pyrrolidine-2-carboxylic acid
Benzyl 3-ethyl-4-methyl-1H-pyrrole-2-carboxylate
C15H17NO2 (243.12592220000002)
1,2,3,4-Tetrahydrocarbazole, TMS derivative
C15H21NSi (243.14431860000002)
3-Hydroxy-N-[(3S)-tetrahydro-2-oxo-3-furanyl]-octanamide
O-Tiglyl-L-carnitine
An O-acyl-L-carnitine compound having trans-2-methyl-2-butenoyl (tiglyl) as the acyl substituent.
2-ethylacryloylcarnitine
An O-acylcarnitine compound having 2-ethylacryloyl as the acyl substituent.
Ala-Gly-Pro
A tripeptide composed of L-alanine, glycine, and L-proline joined in sequence by peptide linkages.
(R)-3-Hydroxytetradecanoate
A (3R)-3-hydroxy fatty acid anion resulting from the deprotonation of the carboxy group of (3R)-3-hydroxytetradecanoic acid. The major species at pH 7.3.
O-Tiglylcarnitine
An O-acylcarnitine compound having trans-2-methyl-2-butenoyl (tiglyl) as the acyl substituent.
2-heptyl-4-quinolone
A quinolone consisting of quinolin-4(1H)-one carrying a heptyl substituent at position 2.
YM348
YM348 is a potent and orally active 5-HT2C receptor agonist, which shows a high affinity for cloned human 5-HT2C receptor (Ki: 0.89 nM).
2-[(2s)-7-methyl-2h,3h-furo[3,2-h]isoquinolin-2-yl]propan-2-ol
C15H17NO2 (243.12592220000002)
(2e,4e)-n-[(2s)-2-methylbutyl]undeca-2,4-dien-8,10-diynimidic acid
(2r)-2,3,3,9-tetramethyl-2h-furo[2,3-b]quinolin-4-one
C15H17NO2 (243.12592220000002)
(3-hydroxybutan-2-yl)[(1e)-3-(c-hydroxycarbonimidoyl)-3-propylprop-1-en-1-yl-oxo-λ⁵-azanylidene]amine
(3s)-2,2,3,9-tetramethyl-3h-furo[2,3-b]quinolin-4-one
C15H17NO2 (243.12592220000002)
2-{7-methyl-2h,3h-furo[3,2-h]isoquinolin-2-yl}propan-2-ol
C15H17NO2 (243.12592220000002)
(2e,4z)-n-(2-methylpropyl)dodeca-2,4-dien-8,10-diynimidic acid
2,3,3,5-tetramethyl-2h-furo[3,2-c]quinolin-4-one
C15H17NO2 (243.12592220000002)
(3-hydroxybutan-2-yl)[3-(c-hydroxycarbonimidoyl)-3-propylprop-1-en-1-yl-oxo-λ⁵-azanylidene]amine
4-{1h,2h,3h,4h,9h-pyrido[3,4-b]indol-1-yl}butan-1-amine
(2r,3r,4s)-3-methyl-2-[(1e,3e)-4-phenylbuta-1,3-dien-1-yl]piperidin-4-ol
4-methoxy-3-(3-methylbut-2-en-1-yl)quinolin-2-ol
C15H17NO2 (243.12592220000002)
(3s)-3-hydroxy-n-[(3s)-2-oxooxolan-3-yl]octanimidic acid
2,2,10-trimethyl-3h,4h-pyrano[2,3-b]quinolin-5-one
C15H17NO2 (243.12592220000002)
(2r)-2,3,3,5-tetramethyl-2h-furo[3,2-c]quinolin-4-one
C15H17NO2 (243.12592220000002)
(1z)-2-hydroxy-1-(1h-indol-3-yl)-5-methylhex-1-en-3-one
C15H17NO2 (243.12592220000002)
(3s,7r)-7-hexyl-5-hydroxy-3-(hydroxymethyl)-6,7-dihydro-3h-1,4-oxazepin-2-one
2,3,3,9-tetramethyl-2h-furo[2,3-b]quinolin-4-one
C15H17NO2 (243.12592220000002)
4-hydroxy-1-methyl-3-(3-methylbut-3-en-2-yl)quinolin-2-one
C15H17NO2 (243.12592220000002)
7-hexyl-5-hydroxy-3-(hydroxymethyl)-6,7-dihydro-3h-1,4-oxazepin-2-one
methyl 1-(2-methylbut-3-en-2-yl)indole-3-carboxylate
C15H17NO2 (243.12592220000002)
3-{[5-(acetyloxy)-1-hydroxy-3-methylpent-2-en-1-ylidene]amino}propanoic acid
C11H17NO5 (243.11066720000002)
(5s)-5-hydroxy-5,7,7-trimethyl-6h,8h-cyclopenta[g]isoquinolin-9-one
C15H17NO2 (243.12592220000002)
3-{[(2z)-5-(acetyloxy)-1-hydroxy-3-methylpent-2-en-1-ylidene]amino}propanoic acid
C11H17NO5 (243.11066720000002)
n-(2-methylbutyl)undeca-2,4-dien-8,10-diynimidic acid
(6e,8e)-9-(7-methyl-7h-azepin-2-yl)nona-6,8-dien-3-one
(2e)-n-(2-methylpropyl)dodeca-2,4-dien-8,10-diynimidic acid
(2e,4e)-n-(2-methylbutyl)undeca-2,4-dien-8,10-diynimidic acid
n-(2-methylpropyl)dodeca-2,4-dien-8,10-diynimidic acid
(2e,4z)-n-[(2s)-2-methylbutyl]undeca-2,4-dien-8,10-diynimidic acid
(2e,4z)-n-(2-methylbutyl)undeca-2,4-dien-8,10-diynimidic acid
5-hydroxy-5,7,7-trimethyl-6h,8h-cyclopenta[g]isoquinolin-9-one
C15H17NO2 (243.12592220000002)
(5r,5as)-5-hydroxy-5,7,7-trimethyl-5ah,6h-cyclopenta[g]isoquinolin-9-one
C15H17NO2 (243.12592220000002)
(2s)-1-(2-{[(2s)-2-amino-1-hydroxypropylidene]amino}acetyl)pyrrolidine-2-carboxylic acid
(2z,4e)-n-(2-methylbutyl)undeca-2,4-dien-8,10-diynimidic acid
(2r)-6-hydroxy-2-[(4r)-2-iminoimidazolidin-4-yl]-6-methylheptanoic acid
(2e,4e)-n-(2-methylpropyl)dodeca-2,4-dien-8,10-diynimidic acid
(2z,4e)-n-(2-methylpropyl)dodeca-2,4-dien-8,10-diynimidic acid
5-hydroxy-5,7,7-trimethyl-5ah,6h-cyclopenta[g]isoquinolin-9-one
C15H17NO2 (243.12592220000002)